LB Pharmaceuticals

LBRX · Nasdaq · United States

Share price · LBRX

$40.06-8.71 (-17.86%) 3M

close as of 2026-11-18 · 24h delayed · vol 356K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LBRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-6.3%
  2. 6 Nov 2026+10.3%
  3. 5 Oct 2026-6.4%

    Nothing announced by LBRX that day or the session before.

  4. 14 Aug 2026+7.9%

    Nothing announced by LBRX that day or the session before.

  5. 3 Aug 2026+6.9%

    Nothing announced by LBRX that day or the session before.

  6. 29 Jul 2026+11.6%
  7. 22 Jul 2026+10.9%
  8. 17 Jun 2026+8.6%

    Nothing announced by LBRX that day or the session before.

  9. 15 Apr 2026+9.6%

    Nothing announced by LBRX that day or the session before.

  10. 5 Feb 2026+12.7%

Share of unusual movement by asset

For each asset, the share of LBRX's own-move activity since 12 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
LB-102 (methylated amisulpride)
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—11%
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—74%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Dopamine D2/D3 receptor + 5-HT7 receptorSmall molecule
Major Depressive DisorderSchizophrenia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (7)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$52M$215M+ $189M short-term inv.$59M-$64M operating cash flowreport ↗
View 6 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$44M$283M+ $45M short-term inv.$52M-$38M operating cash flowreport ↗
2026-Q1—$15M$321M+ $45M short-term inv.$19M-$23M operating cash flowreport ↗
2025-Q3—$2.4M$270M+ $45M short-term inv.$3.6M-$3.4M operating cash flowreport ↗
2025-Q2—$2.4M—$4.9M-$5.6M operating cash flowreport ↗
2025-Q1—$3.4M—$5.3M-$8.1M operating cash flowreport ↗
2024-Q3—$11M—$14Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$17M$250M+ $45M short-term inv.$6.3M-$35M operating cash flowreport ↗

LB Pharmaceuticals reported R&D spend of $16.74M, down 67.3% YoY, cash and equivalents of $250.17M, and a net loss of $25.2M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$51M$23M+ $5.0M short-term inv.$16M-$53M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-09Miller Joseph M · Chief Financial OfficerAward / grant (derivative)200,000——Form 4
2026-10-09Kozauer Susan Gani · Chief Medical OfficerAward / grant (derivative)200,000——Form 4
2026-07-30Deep Track Biotechnology Master Fund, Ltd.; Deep Track Capital, LP; KROIN DAVID · 10% owner; 10% owner; 10% ownerOpen-market purchase (derivative)286,205$34.94$10.0MForm 4
2026-06-03Garland J. Scott · directorAward / grant (derivative)10,000——Form 4
2026-06-03Kane William P Jr · directorAward / grant (derivative)10,000——Form 4
2026-06-03Hemrajani Rekha · directorAward / grant (derivative)10,000——Form 4
2026-06-03Lenz Robert A. · directorAward / grant (derivative)12,500——Form 4
2026-06-03Luse Rebecca · directorAward / grant (derivative)10,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 77 reporting institutions held 28.3M shares ($693.3M, 98.5% of shares outstanding).

#InstitutionSharesValue
1Deep Track Capital, LP3,352,804$82.7M
2BlackRock, Inc.2,470,845$60.9M
3RA CAPITAL MANAGEMENT, L.P.2,208,604$54.5M
4TCG Crossover Management, LLC1,839,489$45.3M
5Commodore Capital LP1,500,000$37.0M
6Caligan Partners LP1,438,070$34.6M
7Spruce Street Capital LP1,376,159$33.6M
8JPMORGAN CHASE & CO1,427,568$33.2M
9Trails Edge Capital Partners, LP1,319,362$32.5M
10Nantahala Capital Management, LLC1,052,894$26.0M
11Balyasny Asset Management L.P.923,694$22.8M
12Logos Global Management LP915,000$22.6M
13VANGUARD CAPITAL MANAGEMENT LLC894,653$22.1M
14Alyeska Investment Group, L.P.863,947$21.3M
15Vivo Capital, LLC800,000$19.7M